Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐<scp>Helicobacter pylori</scp> quadruple therapies

Fischbach, Lori; Zanten, Sander Veldhuyzen van; Dickason, John

doi:10.1111/j.1365-2036.2004.02248.x

Cited by 186 publications

(173 citation statements)

References 82 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…We couldn't detect a statistically significant difference between the regimen types (triple or quadruple regimens) with respect to the gastrointestinal side-effects. In one meta-analysis which was done in 2004, it was found that the occurrence of adverse events was consistently similar for the triple or quadruple regimens in the 10 controlled trials [20].…”

Section: Discussionmentioning

confidence: 99%

The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

Abbasinazari

Sahraee²,

Mirahmadi³

2013

JCDR

View full text Add to dashboard Cite

Background: Helicobacter pylori is a major cause of upper gastrointestinal disorders. The eradication of H. pylori has been recommended for the treatment of different gastrointestinal diseases. Notwithstanding, a combination therapy is needed for Helicobacter pylori eradication, but using these medications can be the cause, the incidence risk of patients' adherence to treatment regimens reduction and probably increase risk of Adverse Drug Reactions (ADRS), so, it is seem that evaluation the out come of combination therapy is need more than the past. Aim:The aim of present study was to determine the patients' adher ence to the treatment and the ADRs with five eradiation regimens. Setting and Design:A cross sectional study was done in a well known referral clinic of gastrointestinal disorders in Tehran, Iran. Methods and Materials:Ninety patients were evaluated the study (18 in each of the five regimens). The adherence to the treatment and the ADRs of the patients were asked during the treatment, twice, by doing telephone assays. Statistical Analysis Used:The data were analyzed by using the SPSS, 17 software and the statistical significance was accepted for the P values of 0.05.

show abstract

Section: Discussionmentioning

confidence: 99%

The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

Abbasinazari

Sahraee²,

Mirahmadi³

2013

JCDR

View full text Add to dashboard Cite

show abstract

“…Recommended treatment duration varies according to individual guidelines; for instance, a treatment duration of more than 1 wk is recommended in Europe, while 1-2 wk and 1 wk are recommended in the United States and South Korea, respectively [8,15,16] . One report indicated that in some metronidazole-resistant areas, extending the bismuth-based quadruple therapy treatment duration to 10-14 d was highly effective [17] ; similarly, another study found that administering metronidazole for 14 d could overcome the negative influence of metronidazole resistance [18] . There is also much debate about the value and efficacy of 7-vs 14-d of bismuth-based quadruple therapy as a second-line eradication therapy in South Korea [14,19,20] .…”

Section: Introductionmentioning

confidence: 99%

Fourteen-vsseven-day bismuth-based quadruple therapy for second-lineHelicobacter pylorieradication

Hwang

Lee

et al. 2015

WJG

View full text Add to dashboard Cite

AIM:To compare the efficacy of 14-and 7-d bismuthbased quadruple therapies as second-line eradication treatment for Helicobacter pylori (H. pylori ) infection. METHODS:Between 2004 and 2014, the medical records of 790 patients who had experienced failure of first-line proton pump inhibitor (PPI)-based eradication therapy and were then treated with bismuth-based quadruple therapy were retrospectively reviewed. Those who received bismuth-based quadruple therapy [PPI, bismuth, metronidazole, and tetracycline (PBMT)] for either 7 d or 14 d were assigned to a PBMT-7 group (n = 543) or a PBMT-14 group (n = 247), respectively. The eradication rates for both groups were determined by intention-to-treat (ITT) and per-protocol (PP) analyses. ITT analysis compared the treatment groups as originally allocated while the PP analysis including only those patients who had completed the treatment as originally allocated. Successful eradication therapy for H. pylori infection was defined as a negative 13 C-urea breath test 4 wk after the end of eradication treatment. RESULTS:The overall ITT eradication rate was 69.1% (546/790). Final ITT eradication rates were 67.4% (366/543; 95%CI: 63.1%-71.7%) in the PBMT-7 group and 72.8% (180/247; 95%CI: 67.4%-78.2%) in the PBMT-14 group (P = 0.028). The overall PP eradication rate was 80.0% (546/682), and the final PP eradication rates were 78.2% (366/468; 95%CI: 72.1%-84.0%) in the PBMT-7 group and 84.1% (180/214; 95%CI: 76.8%-90.8%) in the PBMT-14 group (P = 0.009). The H. pylori eradication rates in the PBMT-14 group were Retrospective Study ORIGINAL ARTICLEsignificantly higher than in the PBMT-7 group according to both ITT (P = 0.028) and PP analysis (P = 0.009). Compliance was similar in both groups (PBMT-7 group: 97.9%; PBMT-14 group: 96.4%). Adverse event rates were 10.7% (51/478) and 17.1% (38/222) in the PBMT-7 and PBMT-14 groups, respectively (P = 0.487). CONCLUSION:

show abstract

“…Adverse events were reported in up to 50% of patients receiving triple therapy. 30 Most of the adverse events were mild, and did not lead to the discontinuation of therapy. In particular, antibiotic administration is often associated with gastrointestinal side effects, such as diarrhea, nausea, vomiting, bloating, and abdominal pain.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer

Ahn

et al. 2018

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

Background/Aims: We aimed to compare the outcomes and timing of Helicobacter pylori eradication in patients with iatrogenic and peptic ulcers. Materials and Methods: This was a retrospective study of 183 patients treated between 2012 and 2015 with 7-day standard triple therapy after endoscopic resection (ER). The patients were enrolled as the iatrogenic ulcer group and assigned to an early treatment group (n=139, H. pylori eradication initiated 2 days after ER) and a late treatment group (n=44, 8 weeks after ER). During the same period, 152 patients with peptic ulcer were assigned to the peptic ulcer group. Results: Successful H. pylori eradication was achieved in 141 patients (77.0%) in the iatrogenic ulcer group and 114 (75.0%) in the peptic ulcer group (P=0.661). Among the ER patients, the eradication rate was 79.9% (n=111) in the early treatment group and 68.2% (n=30) in the late treatment group (P=0.109). The adverse event rate was significantly higher in the peptic ulcer group than in the iatrogenic ulcer group (13.8% vs. 4.9%, P=0.005). Compliance and adverse events did not significantly differ between the early and late treatment groups. Conclusions: In iatrogenic ulcer, H. pylori eradication can be performed with a relatively lower adverse event rate, regardless of treatment timing, than that in peptic ulcer. (Korean J Helicobacter Up Gastrointest Res 2018;18:30-37)

show abstract

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Cited by 186 publications

References 82 publications

The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

The Patients’ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens

Fourteen-vsseven-day bismuth-based quadruple therapy for second-lineHelicobacter pylorieradication

Helicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer

Contact Info

Product

Resources

About